LOGIN  |  REGISTER
Recursion

List of Biotech and Pharma Companies Using Artificial Intelligence

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 55.99
0.00 0.00
0
17.36M
US$ 971.990M
US$ 809.35
-10.01 -1.22
1.83M
899.32M
US$ 727.860B
US$ 40.26
-0.98 -2.38
650,949
5.52B
US$ 222.240B
US$ 377.27
-0.03 -0.01
397,310
381.22M
US$ 143.820B
US$ 312.31
-5.09 -1.60
546,665
278.15M
US$ 86.870B
US$ 282.51
-0.04 -0.01
571,737
162.35M
US$ 45.870B
US$ 72.70
0.44 0.61
1.54M
456.87M
US$ 33.210B
US$ 83.37
1.38 1.68
1.61M
390.60M
US$ 32.560B
US$ 158.72
1.83 1.17
871,579
181.50M
US$ 28.810B
US$ 106.00
-0.57 -0.53
764,722
239.74M
US$ 25.410B
US$ 182.07
1.86 1.03
485,868
111.62M
US$ 20.320B
US$ 91.65
0.37 0.41
1.24M
199.07M
US$ 18.240B
US$ 64.82
0.07 0.11
885,807
225.72M
US$ 14.630B
US$ 89.85
2.91 3.35
815,595
158.60M
US$ 14.250B
US$ 71.01
3.26 4.81
1.95M
192.65M
US$ 13.680B
US$ 29.39
0.01 0.03
480,972
435.99M
US$ 12.810B
US$ 146.35
0.69 0.47
566,569
82.56M
US$ 12.080B
US$ 95.89
2.34 2.50
595,066
121.70M
US$ 11.670B
US$ 72.13
0.84 1.18
8.41M
152.40M
US$ 10.990B
US$ 47.34
0.23 0.49
698,583
222.26M
US$ 10.520B
US$ 100.50
-4.26 -4.07
722,217
86.66M
US$ 8.710B
US$ 51.04
0.51 1.01
738,591
158.89M
US$ 8.110B
US$ 150.38
0.93 0.62
452,229
51.14M
US$ 7.690B
US$ 36.10
4.12 12.88
559,502
186.89M
US$ 6.750B
US$ 38.87
-0.06 -0.15
548,355
172.09M
US$ 6.690B
US$ 143.71
-0.14 -0.10
153,336
31.30M
US$ 4.500B
US$ 58.14
2.73 4.93
416,858
74.03M
US$ 4.300B
US$ 21.66
-0.40 -1.81
1.51M
101.66M
US$ 2.200B
US$ 22.26
0.07 0.32
438,086
86.43M
US$ 1.920B
US$ 66.07
1.50 2.32
377,891
27.47M
US$ 1.810B
US$ 10.67
-0.34 -3.09
1.55M
160.99M
US$ 1.720B
US$ 41.36
0.47 1.15
209,229
38.23M
US$ 1.580B
US$ 2.91
0.02 0.69
4.43M
412.08M
US$ 1.200B
US$ 6.93
0.07 1.02
2.40M
172.17M
US$ 1.190B
US$ 10.93
0.51 4.89
2.22M
107.00M
US$ 1.170B
US$ 6.53
-0.15 -2.25
1,981
162.86M
US$ 1.060B
C$ 3.94
0.02 0.51
866,145
248.96M
C$ 980.900M
US$ 8.23
-0.04 -0.48
1.33M
115.03M
US$ 946.700M
US$ 17.21
-0.04 -0.23
227,558
35.82M
US$ 616.460M
US$ 7.97
0.18 2.31
395,694
77.11M
US$ 614.570M
US$ 5.79
-0.12 -2.03
822,539
89.70M
US$ 518.910M
US$ 6.60
-0.03 -0.45
140,845
78.15M
US$ 515.790M
US$ 2.86
0.005 0.18
1.19M
168.92M
US$ 482.270M
US$ 4.94
-0.09 -1.79
625,206
91.04M
US$ 449.740M
US$ 2.32
0.02 0.65
2.07M
186.64M
US$ 432.070M
US$ 3.05
-0.16 -4.84
1.83M
138.95M
US$ 423.100M
US$ 16.73
0.69 4.30
65,323
23.48M
US$ 392.700M
US$ 2.27
-0.06 -2.58
89,164
153.83M
US$ 349.190M
US$ 2.82
0.04 1.26
1.44M
114.86M
US$ 323.330M
US$ 5.14
0.09 1.79
471,595
58.52M
US$ 300.500M
US$ 9.75
-1.25 -11.36
1,400
27.08M
US$ 264.030M
US$ 13.85
-0.42 -2.94
180,787
18.42M
US$ 255.120M
US$ 3.84
0.04 1.05
242,012
60.85M
US$ 233.660M
C$ 1.35
0.00 0.00
969,926
165.88M
C$ 223.940M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 2.93
0.06 2.09
26,697
66.44M
US$ 194.670M
US$ 7.50
0.06 0.81
6,624
23.12M
US$ 173.400M
US$ 4.03
-0.03 -0.74
70,424
40.44M
US$ 162.970M
US$ 3.66
0.36 10.97
513,153
32.20M
US$ 117.920M
US$ 2.35
0.00 0.00
0
49.43M
US$ 116.160M
US$ 0.83
0.0025 0.30
469,171
125.80M
US$ 104.790M
C$ 1.41
0.05 3.68
51,914
74.08M
C$ 104.450M
US$ 3.88
0.20 5.43
361,973
26.35M
US$ 102.240M
US$ 1.72
0.01 0.76
14,937
37.10M
US$ 63.920M
US$ 1.95
0.00 0.00
0
31.02M
US$ 60.490M
US$ 0.35
-0.02 -5.56
2.31M
158.72M
US$ 54.760M
US$ 1.43
-0.005 -0.35
552,306
37.42M
US$ 53.320M
US$ 1.82
-0.03 -1.62
389,823
27.60M
US$ 50.230M
US$ 1.67
0.16 10.60
565,612
26.67M
US$ 44.540M
US$ 2.03
0.06 2.84
264,216
20.75M
US$ 42.040M
US$ 0.72
-0.007 -0.97
1.09M
57.89M
US$ 41.390M
US$ 1.86
-0.02 -1.06
9,982
21.67M
US$ 40.310M
US$ 2.15
0.08 3.86
178,178
16.26M
US$ 34.960M
US$ 3.21
0.16 5.25
147,391
10.78M
US$ 34.600M
C$ 0.32
0.00 0.00
11,800
90.89M
C$ 29.080M
US$ 1.25
0.03 2.46
35,092
22.41M
US$ 28.010M
US$ 0.82
0.12 17.18
2.70M
31.06M
US$ 25.530M
C$ 0.15
0.00 0.00
41,500
159.67M
C$ 23.950M
US$ 0.30
0.00 0.00
671,346
77.45M
US$ 23.240M
C$ 0.23
-0.005 -2.13
65,243
93.38M
C$ 21.480M
C$ 0.15
0.00 0.00
0
140.64M
C$ 21.100M
US$ 2.49
-0.01 -0.40
8,386
8.39M
US$ 20.890M
US$ 0.05
-0.0035 -7.07
146,167
407.29M
US$ 18.740M
US$ 0.74
0.01 1.67
203,878
22.45M
US$ 16.570M
US$ 3.05
-0.19 -5.86
343,768
5.43M
US$ 16.560M
US$ 1.74
0.05 2.96
60,852
8.71M
US$ 15.160M
US$ 2.04
0.00 0.00
0
7.09M
US$ 14.440M
US$ 0.54
0.02 3.85
2,875
24.39M
US$ 13.170M
US$ 1.09
-0.02 -1.36
100,800
10.63M
US$ 11.530M
US$ 0.44
-0.01 -2.44
1.15M
23.26M
US$ 10.230M
C$ 0.11
0.00 0.00
1,500
96.40M
C$ 10.120M
US$ 0.35
0.03 8.49
1.52M
27.99M
US$ 9.800M
US$ 1.34
0.04 3.00
1.05M
6.90M
US$ 9.240M
C$ 0.08
0.00 0.00
0
100.02M
C$ 7.500M
US$ 0.51
0.006 1.19
80,908
14.09M
US$ 7.190M
US$ 2.47
-0.01 -0.40
81,287
2.71M
US$ 6.690M
US$ 0.96
-0.004 -0.42
66,595
6.67M
US$ 6.380M
US$ 1.42
-0.009 -0.63
15,090
4.22M
US$ 6.000M
C$ 0.06
0.00 0.00
366,500
90.29M
C$ 5.420M
C$ 0.04
0.00 0.00
0
133.13M
C$ 5.330M

Latest News From Biotech and Pharma Companies Using Artificial Intelligence


Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services. As part of an ongoing... Read more


AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Breakthrough in AI-powered drug discovery validates HYFT™-driven peptide design, with broad potential across multiple therapeutic areas AUSTIN, Texas / Jun 12, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior... Read more


Cigna Healthcare Unveils Industry-Leading AI-Powered Digital Tools for a Simple and Reliable Customer Experience

New features blend innovation, responsible AI, and human interactions to better support customers in their health care journeys As new data show 4 out of 5 U.S. adults don't feel confident in their knowledge of health insurance benefits, new digital tools use clear, conversational language to boost understanding and help customers get more out of their coverage BLOOMFIELD, Conn., June 12, 2025 /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna... Read more


IQVIA Launches New AI Agents for Life Sciences and Healthcare

RESEARCH TRIANGLE PARK, N.C. / Jun 11, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA’s new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI... Read more


HEALWELL AI Leverages Orion Health to Power Entry into US Market

HEALWELL launches in the U.S. market a suite of AI enabled tools to complement Orion Health's established software offerings in the U.S. This will bring together HEALWELLs globally validated AI capabilities with Orion Health's best-in-class health data infrastructure software creating a unique offering for the U.S. market. This U.S. market launch leverages Orion Health's deep U.S. sector experience, existing U.S. footprint and multi-decade track record of delivering... Read more



ImmunoPrecise Antibodies Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes. AUSTIN, Texas / Jun 05, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai™ platform powered by their patented HYFT® technology. This discovery, made using several proprietary... Read more


RadNet Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics

See-Mode’s commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet’s DeepHealth population health solutions Real-world deployment of See-Mode’s FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy The acquisition positions RadNet at the forefront of AI innovation in ultrasound LOS... Read more


Perimeter Medical Imaging AI Launches OCT-Tissue Registry to Power AI and Imaging Innovation

Registry aims to collect thousands of images and data from surgeries performed nationwide TORONTO and DALLAS, June 4, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company") announced today that it has launched the OCT-Tissue Surveillance Registry, a database that aims to collect thousands of images and data from surgical procedures performed using the company's imaging technology. Perimeter will use the registry to... Read more


MindBio Therapeutics: Booze AI, the World's First Voice-Activated AI Powered Blood Alcohol Estimator over a Smartphone, Launches in Silicon Valley

MindBio debuts app.booze-ai.com to investors in Silicon Valley Vancouver, British Columbia – TheNewswire - June 3, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company has today launched Booze AI, in Silicon Valley, debuting the world’s first AI-driven, voice-activated blood alcohol concentration (BAC) estimator for use on smartphones, tablets and computers to 150... Read more


Tempus AI Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling CHICAGO / May 31, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary dataset to generate valuable insights for both patient care and... Read more


Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory... Read more


GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

Company deploying AI to scale industry-leading rare disease dataset to diagnose growing number of patients with genetic disease, published in the American Journal of Medical Genetics GAITHERSBURG, Md. / May 22, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the publication of a new article in the American Journal of Medical Genetics, demonstrating GeneDx’s leadership in applying... Read more


Warby Parker Partners with Google To Develop Intelligent Eyewear

AI-Powered Glasses Will Be Designed for All-Day Wear Announcement Marks First Eyewear Partnership for Android XR Google Commits Up to $150M, Including an Equity Investment in Warby Parker, as Part of Long-Term Commitment to Partnership NEW YORK / May 20, 2025 / Business Wire / Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced a partnership with Google to develop AI-powered glasses intended... Read more


Mobile-health Network Solutions Signs MOU to Add AI-enabled Dental Scans and Oral Health Screening to its Telemedicine Platform

Singapore, Singapore--(Newsfile Corp. - May 20, 2025) - Mobile-health Network Solutions (Nasdaq: MNDR) ("MNDR" or "the Company"), a leading MedTech innovator ranked among Asia-Pacific's high-growth companies, today unveiled a new tele-dentistry service that is soon expected to let patients perform an AI-enhanced dental scan at home using the Company's MaNaDr telemedicine app, with expert-reviewed reports delivered within 24 hours. The service, which MNDR will market to... Read more


PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to formally announce the launch of the Phenesafe AI platform, an AI technology stack specifically designed to derive novel substituted phenethylamine molecules for patent and... Read more


GE HealthCare launches CleaRecon DL, introducing AI-based 3D reconstruction to the interventional suite

CleaRecon DL receives 510(k) clearance and CE mark, paving the way for clinicians to use 3D image guidance technologies to their full potential with the goal of achieving better clinical and operational outcomes AI-driven solution advances image quality and improves clinical confidence, encouraging adoption of cone-beam computed tomography CHICAGO / May 15, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced the launch of CleaRecon DL, technology powered... Read more


Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it has launched Augusta, a Precision Neurology Platform for patient stratification,... Read more


Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced the Company has completed its research program as part of the Israel Innovation Authority’s MAGNET incentive program, the Human Robot Interaction Consortium (the “HRI Consortium”). This... Read more


Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive... Read more


WELLSTAR Technologies Launches Nexus AI: A Transformative AI Platform for Canadian Healthcare Providers

WELL Health subsidiary WELLSTAR launches Nexus AI™, an AI platform that provides next-generation ambient scribe capabilities with a reimagined user experience. It has been built to serve as the hub for expanding automated AI and agentic capabilities, including disease detection, medical coding, billing automation, and other clinical decision support. This release builds on the success of WELLSTAR’s first generation AI Scribe with significantly expanded functionality. Nexus... Read more



Tempus AI Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry

CHICAGO / May 05, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients’ electronic health... Read more




iRhythm Technologies Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection

iRhythm Zio® Long-Term Continuous Monitoring (LTCM) system — commercially introduced in Japan as the Zio® ECG Recording and Analysis System — brings AI-powered, continuous, uninterrupted ECG monitoring for up to 14 days to Japan Launch is timely amid a growing demand for early, accurate detection of arrhythmias in Japan, the second largest ambulatory cardiac monitoring market in the world, where the prevalence is expected to rise alongside an aging population1-3 SAN... Read more


Rein Therapeutics and Qureight Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its... Read more


Health Catalyst Announces Strategic Partnership with Microsoft to Accelerate AI Adoption and Transformation for Care Delivery Organizations

Health Catalyst's Improvement Expertise Built on Microsoft Azure and Azure AI Foundry to Drive Reliable Insight and Sustained Outcomes for Care Providers SALT LAKE CITY, April 29, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced a strategic partnership with Microsoft to help healthcare organizations accelerate operational, clinical,... Read more


Veeva Systems Announcing Veeva AI

Major new initiative will add AI to Veeva applications and the Veeva Vault Platform to help automate critical industry-specific functions and improve productivity from clinical to commercial PLEASANTON, Calif., April 29, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva AI, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and improve employee productivity using... Read more


Tempus AI Introduces Loop, an AI-Powered Target Discovery and Validation Platform

The new, proprietary target discovery platform integrates RWD, human biological modeling, and CRISPR screens to accelerate novel target identification CHICAGO / Apr 28, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus’ proprietary approach to novel target... Read more



Waystar Launches New Generative AI and Advanced Automation Across Its Software Platform to Address Billions in Administrative Waste

AltitudeAI™ expansion accelerates mission-critical claim processes from days to minutes — unlocking major efficiency gains for providers LEHI, Utah, and LOUISVILLE, Ky., April 23, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, will host an Innovation Showcase today at 2 p.m. ET. At the event, Waystar will unveil numerous new innovations spanning its software platform, including first-to-market generative AI... Read more



Ainos and ugo Complete First Robotic Smell Integration in Japan

Milestone Ignites a New Era of Smell-Enabled Robotics Installs AI Nose in ugo Robot; Real-World Pilots to Begin in Weeks SAN DIEGO, CA / ACCESS Newswire / April 21, 2025 / Ainos, Inc. (Nasdaq:AIMD) (Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, has successfully installed its proprietary AI Nose olfaction module on a humanoid robot developed by ugo, Inc. ("ugo"), Japan's top service robotics company. Completed on April 9, 2025, the installation... Read more



Hyperfine Enrolls Initial Patients in NEURO PMR Study to Evaluate Use of AI-Powered Portable MRI in Neurology Offices

Real-world study will assess clinical utility and patient experience across diverse neurological conditions to support adoption of AI-powered portable MRI systems in the office setting. GUILFORD, Conn. / Apr 15, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system, first approved... Read more


Illumina and Tempus AI partner to drive the future of precision medicine through genomic AI innovation

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation.... Read more


FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and O

SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next generation Ceribell Clarity™ algorithm for the detection of electrographic seizures in patients ages 1 and older. This makes Ceribell... Read more


ReShape Lifesciences Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their next-generation neuromuscular rehabilitation devices in the U.S. The flagship product, the Stimel-03, was showcased at the American Occupational Therapy Association 2025 Annual... Read more


Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence... Read more




Conduit Pharmaceuticals Expands Partnership with Sarborg to Leverage Machine Learning Data Analysis for Pipeline Optimization

Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that it has entered into an additional license and use... Read more


NetraMark And Worldwide Clinical Trials Announce Agreement To Transform Clinical Trial Design With AI-Powered Precision

TORONTO, April 3, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a global agreement with Worldwide Clinical Trials ("Worldwide"), a full-service, global contract research organization (CRO). This strategic partnership introduces... Read more



HEALWELL AI Completes Acquisition of Orion Health, Becoming a Global Leader in Healthcare Data Interoperability and Artificial Intelligence

HEALWELL has acquired Auckland, New Zealand-based Orion Health Holdings Limited ("Orion Health"), a global healthcare intelligence platform providing subscription licenses and services to marquee public sector clients with data interoperability and healthcare navigation products. Orion Health1 has approximately 400 employees with offices in 11 countries globally. Its software solutions currently support over 70 public and private sector customers representing 150 million... Read more


Alpine ENT Expands Partnership with CareCloud, Implements FrontDesk Assist to Enhance Patient Experience

SOMERSET, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company”) (Nasdaq: CCLD, CCLDO), a leading provider of healthcare technology and AI-powered revenue cycle management (RCM) solutions, today announced the expanded adoption of its services by Alpine Ear, Nose & Throat PC, a premier otolaryngology group based in Colorado. Following a successful RCM engagement, Alpine ENT has now implemented CareCloud FrontDesk Assist—a comprehensive front-office... Read more


Charles River Laboratories and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering’s in-house drug development unit WILMINGTON, Mass. & CAMBRIDGE, Mass. / Mar 25, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications... Read more


Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients. VERDI Solutions, headquartered... Read more


Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds represent true drug discovery using Predictive's active machine learning platform PITTSBURGH, March 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has successfully developed predictive... Read more